Abstract

For the induction of antigen-specific T-cell responses by vaccination, an appropriate immune adjuvant is required. Vaccine adjuvants generally provide two functions, namely, immune potentiator and delivery, and many adjuvants that can efficiently induce T-cell responses are known to have the combination of these two functions. In this study, we explored a cationic lipid DOTAP-based adjuvant. We found that the microfluidic preparation of DOTAP nanoparticles induced stronger CD4⁺ and CD8⁺ T-cell responses than liposomal DOTAP. The further addition of Type-A CpG D35 in DOTAP nanoparticles increased the induction of T-cell responses, particularly in CD4⁺ T cells. Further investigations revealed that the size of DOTAP nanoparticles, prepared buffer conditions, and physicochemical interaction with vaccine antigen are important factors for the efficient induction of T-cell responses with a relatively small antigen dose. These results suggested that microfluidic-prepared DOTAP nanoparticles plus D35 are a promising adjuvant for a vaccine that induces therapeutic T-cell responses for treating cancer and infectious diseases.

Microfluidic-prepared DOTAP Nanoparticles Induce Strong T-cell Responses in Mice

Abstract

Advanced Search

Browse by Category

related content

Microfluidic preparation of drug-loaded PEGylated Liposomes, and the Impact of Liposome Size on Tumour Retention and Penetration

Evaluation of Novel Cationic Gene Based Liposomes with Cyclodextrin Prepared by Thin Film Hydration and Microfluidic Systems